Abstract 219P
Background
Retrospective investigations indicate that inhibiting PI3Kδ and/or γ, which are prevalent in leukocytes, elicits an anticancer immune response by reducing the activity of immunosuppressive cells. However, the isolated inhibition of either PI3Kδ or γ is insufficient for the complete eradication of solid tumors.
Methods
We utilized BR101801, a PI3Kδ/γ inhibitor, in the CT-26 syngeneic mouse model with a subcutaneously implanted tumor. BR101801 was delivered on a daily basis, and the target tumor region received localized irradiation. We consistently observed tumor growth and assessed immunological alterations via flow cytometry, ELISpot, and transcriptional analysis. Furthermore, we examined the mechanism of anticancer immunological effects via BR drug and radiation therapy by inhibiting the pathway using antibody treatment.
Results
Together with irradiation, BR101801 reduced Treg proliferation and increased tumor-specific CD8α+ T cells in the tumor microenvironment, leading to tumor regression. Post-irradiation, the CD8α+ T cell to Treg ratio increased for 14 days, causing remote tumor regression in metastatic lesions, known as the abscopal effect. Combining BR101801 with irradiation enhances the immune-stimulatory tumor microenvironment, transforming immunologically cold tumors into hot ones, according to transcriptome analysis. Additionally, we examined CD8 T cell recruiting cells and methods. Previous studies on Batf3, which is involved in IFN-related genes and cross-presentation in cancer, were confirmed. We checked if IFNAR1 antibody administration negated the combined treatment's anticancer activity, and the result showed that only the monotherapy's effect was seen. The previously established CD8 T cell infiltration did not occur, and PMN-MDSC's immunosuppressive impact was eliminated.
Conclusions
Preclinical data indicates that PI3Kδ/γ suppression and irradiation can enhance systemic antitumor immunity against solid tumors, suggesting its potential as an immune-regulatory radiosensitizer.
Legal entity responsible for the study
Boryong Co.
Funding
Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science and ICT (MSIT), The Republic of Korea (No. 50531-2021), and the National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract